滚动资讯
CellComplete biosynthesis of nicotineFierceBiotechCancer screening costs rival diagnosis fears as patients fall behindFierceBiotechEpia Neuro launches with BCI device to help stroke patients rework brain signalsEndpoints NewsNovo and Lilly battle over GLP-1 claims only a head-to-head trial can answerEndpoints NewsDrug substance maker raises prices due to energy crisis; SpectronRX gets $85MEndpoints NewsLipocine's postpartum depression drug fails; AstraZeneca claims liver cancer winEndpoints NewsTrump is preparing 100% tariffs on some drugmakers, documents showBioWorldHoliday noticeEndpoints NewsClaim of ChatGPT treating Rosie the dog's cancer stirs AI biotech debateIlluminaIllumina (NASDAQ: ILMN) nominates David P. King as three directors retire - Stock TitanIlluminaThree Illumina directors are leaving as the company puts David King on its board slate - Stock TitanIlluminaIllumina Announces Changes to Board of Directors - PR Newswire
FierceBiotech 2026年4月2日

Cancer screening costs rival diagnosis fears as patients fall behind

Cancer screening costs rival diagnosis fears as patients fall behind

原文
暂时没有全文，请查看原始来源。

目录

59 全部